Supporting female founder initiatives across the UK & Ireland

Find out more  
← Back to portfolio Porfolio / TidalSense (formerly CRI)

TidalSense (formerly CRI)

Company overview

The medtech company TidalSense, formerly Cambridge Respiratory Innovations (CRI), creates ground-breaking respiratory technologies.

TidalSense first received funding from BGF and Downing Ventures in December 2020, to fast-track research and development of its award-winning N-Tidal device.

The N-Tidal device is a first-in-kind, connected, handheld capnometer incorporating unique patented sensor technology, that can accurately measure carbon dioxide levels in exhaled breath during normal breathing. It helps medical professionals diagnose and monitor respiratory conditions.

Website
tidalsense.com

Company information

Head office
  • Cambridge
CEO
  • Dr Ameera Patel
BGF office
Investment date
  • Dec 2020